Drug access extended for cancer patients who responded well
NCT ID NCT02875548
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study offers continued access to the drug tazemetostat for 58 people with certain cancers who previously benefited from it in other trials. The main goal is to track long-term safety and how long participants stay on the drug. It is not a cure but helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Astera Cancer Center
East Brunswick, New Jersey, 08816, United States
-
Beatson, West of Scotland Cancer Centre
Glasgow, United Kingdom
-
CHRU de Lile- Hopital Claude Huriez
Lille, 59037, France
-
CHU Rennes- Hopital Pontchaillou
Rennes, 35033, France
-
CHU de Caen - Hôpital Côte de Nacre
Caen, 14033, France
-
CHU de Montpellier - Hopital Saint Eloi
Montpellier, France
-
California Cancer Associates For Research And Excellence, cCARE
Santa Fe, California, 92024, United States
-
Central Care Cancer Center
Bolivar, Missouri, 65613, United States
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
-
Clatterbridge Cancer Centre
Liverpool, L7 8XP, United Kingdom
-
Columbia University Medical Center
New York, New York, 10019, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David H. Koch Center for Cancer Care at memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Geelong Hospital
Geelong, Australia
-
Gustave Roussay
Villejuif, 94805, France
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hematology Oncology Associates of the Treasure Coast - Port St. Lucie
Port Saint Lucie, Florida, 34952, United States
-
Hôpital Saint Louis - AP-HP
Paris, 75010, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Moffitt
Tampa, Florida, 33612, United States
-
Monash Health
Monash, Australia
-
Monash Medical Centre- Monash Campus
Clayton, 3168, Australia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej
Warsaw, Poland
-
Oncology and Haematology Clinical Trials Unit
Leicester, LEI 5WW, United Kingdom
-
Peter MacCallum Cancer Institute
Melbourne, 3002, Australia
-
Pratia MCM Krakow
Krakow, 30-510, Poland
-
Princess Alexandra Hospital
Alexandra, Australia
-
S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine"
Kharkiv, 61024, Ukraine
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University Hospital (UZ) Leuven
Leuven, 3000, Belgium
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.